• Robust manufacturing processes are needed to transform human health by cell therapies
  • An ERC that engages stakeholders in fundamental multi-disciplinary team-oriented manufacturing research will transform the cell manufacturing industry
  • MSCs, engineered T cells, and iPSC-derived cardiomyocyte testbeds represent current and future cell manufacturing process
  • Synergistic thrusts will enable development of efficient, robust, scalable, cost-effective manufacturing of safe and potent cell therapies
  • CMaT researchers are leaders of the field and are well-poised to thrive in cross-cutting integrative research
  • CMaT students will comprise a diverse, highly-trained multidisciplinary workforce who will lead the revolution in cell therapy manufacturing

 

CMaT Vision

CMaT 3 Plane Chart